DR won’t be able to promote weight reduction medicine in India Reddy’s and Onesource, Delhi Excessive Court docket stayed as a consequence of patent dispute
Semaglutide Patent Dispute: Delhi Excessive Court docket has issued an vital interim order within the patent dispute associated to Denmark’s drug firm Novo Nordisk’s well-known anti-dibitic and anti-obesity drug semaglutide. Court docket did Dr. Reddy’s Laboratories and Onesource Specialty Pharma have been stopped from gross sales and advertising of this drug in India. Nonetheless, they’re … Read more